Canadian anticancer drug company: Aeterna Zentaris (AEZS) (1991)

Aeterna Zentaris Inc. (NASDAQ: AEZS) was founded in 1991 and is headquartered in Quebec City, Canada. It has 56 full-time employees. It is a biopharmaceutical company focusing on the research and development of oncology and endocrine system diseases and women’s health products. Sales.

Aeterna Zentaris AEZS Logo

Aeterna Zentaris (AEZS):

Aeterna Zentaris Inc. is a biopharmaceutical company that develops drugs for the treatment of tumors and endocrine diseases. Its products include:

  1. MACRILEN-used for growth hormone deficiency, and at the same time increase treatment to induce cancer cachexia, currently in the IIa clinical trial stage;
  2. ZoptEC-for endometrial cancer, currently in the phase III clinical trials for the treatment of recurrent or metastatic endometrial cancer;
  3. AEZS-120-a recombinant oral tumor vaccine, currently in the preclinical stage;
  4. PI3K/ERK inhibitors AEZS-129 and AEZS-136;
  5. disora​​zol Z products AEZS-137 and AEZS-138.
Notify of
Inline Feedbacks
View all Intels

Cable TV equipment supplier: ADDvantage Technologies Group (AEY) (1989)

Israeli retailer: Alon Blue Square Israel (BSI) (1988)